Avalo Therapeutics (NASDAQ:AVTX) Posts Earnings Results

Avalo Therapeutics (NASDAQ:AVTX) released its quarterly earnings results on Wednesday. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.02, FiscalAI reports.

Avalo Therapeutics Stock Down 1.0%

Shares of Avalo Therapeutics stock traded down $0.19 during trading on Wednesday, hitting $19.75. The stock had a trading volume of 1,045,331 shares, compared to its average volume of 1,005,265. The stock has a 50 day simple moving average of $15.80 and a 200 day simple moving average of $16.43. The company has a market capitalization of $527.60 million, a PE ratio of -3.45 and a beta of 0.78. Avalo Therapeutics has a 1 year low of $3.39 and a 1 year high of $24.27.

Insider Transactions at Avalo Therapeutics

In other news, insider Mittie Doyle sold 25,492 shares of Avalo Therapeutics stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $16.15, for a total value of $411,695.80. Following the transaction, the insider directly owned 3,622 shares of the company’s stock, valued at $58,495.30. This trade represents a 87.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Christopher Ryan Sullivan sold 8,458 shares of Avalo Therapeutics stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $13.09, for a total transaction of $110,715.22. Following the completion of the transaction, the chief financial officer directly owned 8,880 shares in the company, valued at approximately $116,239.20. This trade represents a 48.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 138,078 shares of company stock valued at $2,501,346 over the last ninety days. Corporate insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Boothbay Fund Management LLC acquired a new stake in shares of Avalo Therapeutics during the second quarter worth approximately $56,000. Dimensional Fund Advisors LP acquired a new stake in shares of Avalo Therapeutics during the third quarter worth approximately $143,000. Jump Financial LLC acquired a new stake in shares of Avalo Therapeutics during the fourth quarter worth approximately $238,000. Persistent Asset Partners Ltd acquired a new stake in shares of Avalo Therapeutics during the fourth quarter worth approximately $274,000. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of Avalo Therapeutics during the fourth quarter worth approximately $305,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on AVTX shares. Wedbush boosted their price target on shares of Avalo Therapeutics from $29.00 to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Wolfe Research began coverage on shares of Avalo Therapeutics in a research note on Thursday, April 9th. They issued an “outperform” rating and a $48.00 price objective on the stock. HC Wainwright lifted their price objective on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. BTIG Research lifted their price objective on shares of Avalo Therapeutics from $40.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Avalo Therapeutics in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Avalo Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $49.63.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.